XML 31 R13.htm IDEA: XBRL DOCUMENT
v3.20.4

Goodwill And Other Intangible Assets | 12 Months Ended
--- | ---
Dec. 31, 2020
Goodwill And Other Intangible Assets [Abstract] |
Goodwill And Other Intangible Assets | 7. Goodwill and Other Intangible Assets Indefinite Lived Intangible Assets As of December 31, 2020 and 2019 the carrying values of our indefinite lived intangible assets are as follows (in thousands):
| 2020 |  | 2019
Goodwill | $ | 260,061 |  | $ | 186,697
In-process R&D |  | 2,392 |  |  | 2,190
Procurement contracts and agreements |  | 2,013 |  |  | 2,013
Trademarks |  | 765 |  |  | 844
We monitor the phases of development of our acquired in-process research and development projects, including the risks associated with further development and the amount and timing of benefits expected to be derived from the completed projects. Incremental costs associated with development are charged to expense as incurred. Capitalized costs are amortized over the estimated useful life of the developed asset once completed. Our in-process research and development projects are reviewed for impairment annually, or more frequently, if events or changes in circumstances indicate that the asset might be impaired. The company did no t record any impairment of indefinite lived intangible assets during the twelve months ended December 31, 2020 and 2019. During the twelve months ended December 31, 2019, the Company received CE Mark for the E-nside multibranch stent graft system for the endovascular treatment of thoraco-abdominal aneurysms. The company reclassed $7.4 million related to the E-nside European business from in-process research and development and into defined lived intangible assets with a useful life of 20 years. Based on our experience with similar agreements, we believe that our acquired procurement contracts and agreements have indefinite useful lives, as we expect to continue to renew these contracts for the foreseeable future. We believe that our trademarks have indefinite useful lives as we currently anticipate that these trademarks will contribute to our cash flows indefinitely. As of December 31, 2020 and 2019 the value of our goodwill, all of which is related to our Medical Devices segment, is as follows (in thousands):
| 2020 |  | 2019
Balance as of January 1, | $ | 186,697 |  | $ | 188,781
Ascyrus acquisition |  | 63,357 |  |  | --
Revaluation of goodwill denominated in foreign currency |  | 10,007 |  |  | (2,084)
Balance as of December 31, | $ | 260,061 |  | $ | 186,697
Definite Lived Intangible Assets As of December 31, 2020 and 2019 gross carrying values, accumulated amortization, and approximate amortization periods of our definite lived intangible assets are as follows (dollars in thousands):
| Gross Carrying |  | Accumulated |  | Amortization
December 31, 2020 | Value |  | Amortization |  | Period
Acquired technology | $ | 222,182 |  |  | 36,091 |  | 11 | – | 22 | Years
Customer lists and relationships |  | 31,316 |  |  | 8,132 |  | 13 | – | 22 | Years
Distribution and manufacturing rights and know-how |  | 14,728 |  |  | 5,349 |  | 5 | – | 15 | Years
Patents |  | 3,966 |  |  | 3,113 |  |  |  | 17 | Years
Other |  | 3,453 |  |  | 1,073 |  | 4 | – | 5 | Years
| Gross Carrying |  | Accumulated |  | Amortization
December 31, 2019 | Value |  | Amortization |  | Period
Acquired technology | $ | 140,193 |  |  | 24,778 |  | 11 | – | 22 | Years
Customer lists and relationships |  | 31,131 |  |  | 6,581 |  | 13 | – | 22 | Years
Distribution and manufacturing rights and know-how |  | 13,826 |  |  | 3,005 |  | 5 | – | 15 | Years
Patents |  | 3,664 |  |  | 3,074 |  |  |  | 17 | Years
Other |  | 1,919 |  |  | 608 |  | 3 | – | 5 | Years
Amortization Expense Amortization expense recorded in general, administrative, and marketing expenses on our Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31 is as follows (in thousands):
| 2020 |  | 2019 |  | 2018
Amortization expense | $ | 13,764 |  | $ | 10,850 |  | $ | 10,792
As of December 31, 2020 scheduled amortization of intangible assets for the next five years is as follows (in thousands):
| 2021 |  | 2022 |  | 2023 |  | 2024 |  | 2025 |  | Total
Amortization expense | $ | 17,095 |  | $ | 16,512 |  | $ | 16,059 |  | $ | 15,707 |  | $ | 13,481 |  | $ | 78,854
‎

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration